Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Read More Share:linkedin| twitter| email

Oct

27

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

Read More Share:linkedin| twitter| email

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Read More Share:linkedin| twitter| email

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Read More Share:linkedin| twitter| email

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:linkedin| twitter| email

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Read More Share:linkedin| twitter| email

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Read More Share:linkedin| twitter| email

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Read More Share:linkedin| twitter| email

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Read More Share:linkedin| twitter| email

Dec

03

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

  • 15 scientific presentations highlight data on BRIVACT® (brivaracetam) CV, NAYZILAM® (midazolam) nasal spray CIV, VIMPAT® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
  • UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel
Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)